Welcome to our dedicated page for Lantheus Holding news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holding stock.
Lantheus Holdings, Inc. (NASDAQ: LNTH) is a radiopharmaceutical-focused company whose news flow centers on diagnostic imaging products, radiopharmaceutical pipeline progress and corporate developments. The company describes its purpose as enabling clinicians to "Find, Fight and Follow" disease, and its announcements frequently highlight advances in PET radiodiagnostics, oncology imaging agents and Alzheimer’s disease diagnostics.
News about Lantheus often covers regulatory milestones for its radiopharmaceutical pipeline. Recent releases include U.S. Food and Drug Administration (FDA) acceptance of a New Drug Application for a new formulation of its piflufolastat F 18 PSMA PET imaging agent, a PDUFA date for LNTH-2501 (Ga 68 edotreotide) for somatostatin receptor-positive neuroendocrine tumors, and FDA acceptance of an NDA for MK-6240, a tau-targeted PET imaging agent for Alzheimer’s disease. These updates provide insight into how the company is expanding its diagnostic portfolio in oncology and neurology.
Lantheus news also frequently addresses business development and portfolio shaping. The company has reported acquisitions of Evergreen Theragnostics and Life Molecular Imaging, adding assets such as OCTEVY and Neuraceq and expanding its capabilities across the radiopharmaceutical value chain. It has also announced the divestiture of its SPECT business to SHINE Technologies, along with licensing agreements such as an exclusive deal with GE HealthCare to develop, manufacture and commercialize PYLARIFY in Japan.
Investors and healthcare professionals following LNTH news can also expect quarterly earnings releases, stock repurchase program announcements, leadership transition updates and conference participation notices. Together, these items provide context on Lantheus’ financial performance, capital allocation, governance and strategic direction in the radiopharmaceutical and medical imaging space.
The Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical has met its co-primary endpoints for detecting Coronary Artery Disease (CAD), exceeding 60% in both sensitivity and specificity. The trial demonstrated higher efficacy than SPECT Myocardial Perfusion Imaging, with over 600 patients participating across multiple regions. If approved, [18F]flurpiridaz’s longer half-life could significantly increase patient access to PET MPI, enhancing diagnostic accuracy and patient outcomes, as noted by experts at the ASNC Congress.
GE Healthcare and Lantheus Holdings have announced that their Phase III clinical trial of the investigational radiotracer [18F]flurpiridaz has successfully met co-primary endpoints for detecting Coronary Artery Disease (CAD), exceeding 60% in both sensitivity and specificity. This trial demonstrated superior diagnostic efficacy compared to SPECT Myocardial Perfusion Imaging. With a half-life approximately 12 times longer than existing PET tracers, [18F]flurpiridaz could significantly improve patient access to PET MPI if approved.
NORTH BILLERICA, Mass., Sept. 01, 2022 – Lantheus Holdings (NASDAQ: LNTH) announced that Bob Marshall, CFO, and Paul Blanchfield, COO, will present at the Wells Fargo Healthcare Conference on September 8 at 8:00 a.m. ET. The presentation will focus on the company’s commitment to innovative diagnostics and therapeutics, including artificial intelligence solutions that enhance patient outcomes. A live webcast can be accessed through the Investors section of the company's website, with a replay available for 30 days.
Lantheus Holdings reported $223.7 million in worldwide revenue for Q2 2022, marking a 121.4% increase from Q2 2021. The company achieved a GAAP net income of $43.1 million, or $0.61 per diluted share, compared to a net loss of $26.7 million in the previous year. Adjusted fully diluted EPS increased to $0.89 from $0.11. Net cash provided by operating activities was $72.6 million, with free cash flow at $68.3 million. The company has raised its full-year revenue guidance to between $885 million and $905 million.
Lantheus Holdings, Inc. (NASDAQ: LNTH) has announced it will host a conference call and webcast on August 4, 2022, at 8:00 a.m. ET to discuss its second-quarter 2022 financial and operating results. Interested participants should register in advance to avoid delays. A replay will be available shortly after the event and archived for at least 30 days. Lantheus, with over 60 years of experience, focuses on improving patient outcomes through diagnostics, radiotherapeutics, and AI solutions.
Lantheus Holdings has announced key management promotions, with Paul Blanchfield becoming Chief Operating Officer and Dottie Barr promoted to Senior Vice President, Manufacturing and Technical Operations. Effective immediately, these changes aim to leverage their expertise for enhanced strategic execution and patient outcomes. Blanchfield, previously Chief Commercial Officer, is recognized for his role in launching the PSMA PET imaging agent for prostate cancer, while Barr has successfully led manufacturing and supply chain improvements despite pandemic challenges.
Lantheus Holdings presented preliminary results of the PD-L1 Expression in Cancer (PECan) study at the SNMMI Annual Meeting. The study focuses on NM-01, a technetium 99m SPECT/CT imaging agent, which aims to assess PD-L1 expression in cancer cells. Preliminary findings indicate that NM-01 can identify patients likely to respond to checkpoint inhibitor therapies, particularly in non-small cell lung cancer (NSCLC). The study included 10 patients, revealing significant insights into PD-L1 expression and treatment response, suggesting NM-01 could enhance patient selection and monitoring in clinical settings.
Lantheus Holdings presented results at the SNMMI Annual Meeting, showcasing the effectiveness of PYLARIFY AI, an FDA-cleared AI platform for PSMA PET/CT scans in prostate cancer. The study highlighted its ability to enhance lesion detection and quantitative assessment compared to manual readings, with significant improvements in diagnostic accuracy and efficiency. The findings reaffirm Lantheus's commitment to integrating AI in oncology, potentially transforming prostate cancer management and improving patient outcomes.
Lantheus Holdings (NASDAQ: LNTH) announced that Mary Anne Heino, CEO, and Bob Marshall, CFO, will present at the Jefferies Healthcare Conference on June 9 at 11:00 a.m. ET. The event will take place in New York City, showcasing the company's commitment to innovative imaging diagnostics and therapeutics. Investors can access a live webcast of the presentation on the company’s website, with a replay available for 30 days post-event. Lantheus is a leader in advanced medical imaging solutions, aiming to enhance patient care through its diverse product portfolio.
Lantheus Holdings, Inc. (NASDAQ: LNTH) announced key presentations at the 2022 SNMMI Meeting in Vancouver, scheduled for June 11-14, 2022. The event will feature oral presentations on two significant imaging agents: PYLARIFY® (piflufolastat F18) for prostate cancer and PYLARIFY AI™, an AI platform for PSMA PET imaging. PYLARIFY's efficacy will be discussed concerning androgen deprivation therapies, while PYLARIFY AI™ will highlight a Phase III study aimed at rapid lesion detection. These advancements reflect Lantheus's commitment to innovative diagnostics and therapeutics in oncology.